Support

Quick links
Frequently asked questions - categories
Ask a question
Contact Us
+1

Thymidine Phosphorylase / PD-ECGF Recombinant Monoclonal Rabbit Antibody (TYMP/2890R)

This antibody recognizes platelet-derived endothelial growth factor (PD-ECGF), same as thymidine phosphorylase (TP) or gliostatin.

Product Attributes

Antibody number

2890

Reactivity (target)

Thymidine Phosphorylase, PD-ECGF

Antibody type

Primary

Host species

Rabbit

Clonality

Recombinant Monoclonal

Clone

TYMP/2890R

Isotype

IgG

Molecular weight

55 kDa

Synonyms

ECGF; ECGF1; Gliostatin; hPD-ECGF; MEDPS1; MNGIE; MTDPS1; PD-ECGF; PDECGF; Platelet-derived endothelial cell growth factor; TdRPase; Thymidine phosphorylase; TP; Tymp

Human gene symbol

TYMP

Entrez gene ID

1890

SwissProt

P19971

Unigene

180903

Immunogen

Recombinant full-length human Thymidine Phosphorylase (TP / PD-ECGF) protein

Cellular localization

Cytoplasmic, Nucleus

Species reactivity

Mouse, Human, Rat

Applications

Immunohistology (formalin)

Positive control

HUVEC cells. Breast, Bladder, Lung or Kaposi tumors

Shipping condition

Room temperature

Storage Conditions

Store at 2 to 8 °C, Protect fluorescent conjugates from light, Note: store BSA-free antibodies at -10 to -35 °C

Shelf life

Guaranteed for at least 24 months from date of receipt when stored as recommended

Regulatory status

For research use only (RUO)

Research areas

Angiogenesis, Metabolism

Primary Antibody Formats:

  • Conjugates: 100 ug/mL  in PBS 0.1% BSA 0.05% azide
  • HRP conjugates: 100 ug/mL in PBS 0.05% BSA, no azide
  • Purified: 200 ug/mL in PBS 0.05% BSA 0.05% azide
  • Purified, BSA-free: 1 mg/mL in PBS, no BSA, no azide

Certificates of Analysis (COA)

Request COA
Conjugation
Size
Catalog #
price
Qty
50 uL
100 uL
250 uL
500 uL
Clear selection
Add to wishlist
ADD TO CART
(Please select quantity above )

Wishlist updated! View wishlist

Shipping, Handling & Tax (CA only) not included in price. Learn more

Tax is assessed in the state of California. All fees will be calculated during checkout based on your shipping information and are subject to change.

SPECIAL - Order 5 or more and receive 10% off.

Request a Bulk Quote

Product Description

This antibody recognizes a protein (amino acid 482) of 55 kDa (in vivo 110 kDa homodimer), identified as platelet-derived endothelial growth factor (PD-ECGF), same as thymidine phosphorylase (TP) or gliostatin. In the presence of inorganic orthophosphate, it catalyzes the reversible phospholytic cleavage of thymidine and deoxyuridine to their corresponding bases and 2-deoxyribose-1-phosphate. It is both chemotactic and mitogenic for endothelial cells and a non-heparin binding angiogenic factor present in platelets. Its enzymatic activity is crucial for angiogenic activity (metabolite is angiogenic). Higher levels of serum TP/PD-ECGF are observed in cancer patients. It is also involved in transformation of fluoropyrimidines, cytotoxic agents used in the treatment of a variety of malignancies, into active cytotoxic metabolites (e.g. 5’-deoxy-5-fluorouridine to 5-FU). High intra-cellular levels of TP/PD-ECGF are associated with increased chemosensitivity to such antimetabolites

Primary antibodies are available purified, or with a selection of fluorescent CF® dyes and other labels. CF® dyes offer exceptional brightness and photostability. See the CF® Dye Brochure for more information. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.

Stock status: Because Biotium offers a large number of antibody and conjugation options, primary antibody conjugates may be made to order. Typical lead times are up to one week for CF® dye and biotin conjugates, and up to 2-3 weeks for fluorescent protein and enzyme conjugates. Please email order@biotium.com to inquire about stock status and lead times before placing your order.

References

O'Brien TS, et. al. Cancer Research, 1996, 56(20):4799-804.| Fox SB, et. al. British Journal of Cancer, 1996, 73:275-8.

 

You may also like…